Interchangeability of Biosimilars: Overcoming the Final Hurdles

Drugs. 2021 Nov;81(16):1897-1903. doi: 10.1007/s40265-021-01629-4.

Authors

Liese Barbier¹, Arnold G Vulto^{2

3}

Affiliations

¹ Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Leuven, Belgium.
² Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000, Leuven, Belgium. a.vulto@erasmusmc.nl.
³ Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands. a.vulto@erasmusmc.nl.

No abstract available

MeSH terms

Biological Products / administration & dosage*
Biosimilar Pharmaceuticals / administration & dosage*
Drug Approval*
Drug Development / methods
Humans
Therapeutic Equivalency

Substances

Biological Products
Biosimilar Pharmaceuticals